NYSEAMERICAN:PTN - Palatin Technologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.33
  • Forecasted Upside: 533.71 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.53
▼ -0.03 (-5.40%)

This chart shows the closing price for PTN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Palatin Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTN

Analyst Price Target is $3.33
▲ +533.71% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Palatin Technologies in the last 3 months. The average price target is $3.33, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 533.71% upside from the last price of $0.53.

This chart shows the closing price for PTN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Palatin Technologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/24/2021HC WainwrightBoost Price TargetBuy$2.00 ➝ $5.00
9/30/2021LADENBURG THALM/SH SHReiterated RatingBuy$2.00
2/18/2021Canaccord GenuityReiterated RatingBuy$3.00
5/12/2020HC WainwrightReiterated RatingBuy$2.00
1/10/2020HC WainwrightLower Price TargetBuy$7.50 ➝ $2.00
11/13/2019HC WainwrightReiterated RatingBuy$7.50
9/13/2019Canaccord GenuitySet Price TargetBuy$6.00
9/13/2019HC WainwrightSet Price TargetBuy$8.00
6/24/2019HC WainwrightSet Price TargetBuy$8.00
5/23/2019LADENBURG THALM/SH SHSet Price TargetBuy$3.00
5/23/2019HC WainwrightSet Price TargetBuy$6.00
5/12/2019LADENBURG THALM/SH SHReiterated RatingBuy$2.75
5/9/2019HC WainwrightBoost Price TargetBuy$5.00 ➝ $6.00
1/11/2019HC WainwrightReiterated RatingBuy$5.00
11/14/2018HC WainwrightSet Price TargetBuy$5.00
9/13/2018HC WainwrightSet Price TargetBuy$5.00
6/27/2018LADENBURG THALM/SH SHInitiated CoverageBuy$3.00
6/4/2018HC WainwrightSet Price TargetBuy$5.00
5/15/2018HC WainwrightSet Price TargetBuy$5.00
4/6/2018HC WainwrightReiterated RatingBuy
4/6/2018HC WainwrightInitiated CoverageBuy$5.00
11/13/2017Canaccord GenuitySet Price TargetBuy$6.00
10/29/2017Roth CapitalSet Price TargetBuy$2.00
9/10/2017Canaccord GenuitySet Price TargetBuy$6.00
6/1/2017Canaccord GenuityReiterated RatingBuy$6.00
5/16/2017Canaccord GenuitySet Price TargetBuy$6.00
2/11/2017Canaccord GenuitySet Price TargetBuy$6.00
1/25/2017Roth CapitalReiterated RatingBuy$1.50
1/24/2017Roth CapitalReiterated RatingBuy
(Data available from 12/5/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/6/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/5/2021
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2021

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Palatin Technologies logo
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
Read More

Today's Range

Now: $0.53
Low: $0.49
High: $0.55

50 Day Range

MA: N/A

52 Week Range

Now: $0.53
Low: $0.33
High: $1.30

Volume

10,457,649 shs

Average Volume

4,426,085 shs

Market Capitalization

$121.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Palatin Technologies?

The following Wall Street sell-side analysts have issued research reports on Palatin Technologies in the last twelve months: Canaccord Genuity, HC Wainwright, LADENBURG THALM/SH SH, and Zacks Investment Research.
View the latest analyst ratings for PTN.

What is the current price target for Palatin Technologies?

3 Wall Street analysts have set twelve-month price targets for Palatin Technologies in the last year. Their average twelve-month price target is $3.33, suggesting a possible upside of 533.7%. HC Wainwright has the highest price target set, predicting PTN will reach $5.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $2.00 for Palatin Technologies in the next year.
View the latest price targets for PTN.

What is the current consensus analyst rating for Palatin Technologies?

Palatin Technologies currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTN will outperform the market and that investors should add to their positions of Palatin Technologies.
View the latest ratings for PTN.

How do I contact Palatin Technologies' investor relations team?

Palatin Technologies' physical mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company's listed phone number is (609) 495-2200 and its investor relations email address is [email protected] The official website for Palatin Technologies is www.palatin.com.